Evidence map›Paper›PMID 30720250›Full record

ReviewEJIFCC1999

New Light Shed On The Enigmatic Eosinophil Granulocyte; A Versatile Cell Of The Immune System.

Arne Egesten, Johan Malm

Open access · greenAbstract readReview
In one paragraph

Review in EJIFCC, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 66% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Arne EgestenDepartments of Internal Medicine.
Johan MalmLaboratory Medicine, Section for Clinical Chemistry, Lund University, University Hospital MAS, Malmö, Sweden.
Malmö University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Eosinophils normally constitute only a few per cent of circulating leukocytes, though they are more numerous in tissues vulnerable to attack by environmental microorganisms. Eosinophils can kill invasive parasites, but they also have immunoregulatory functions and may be involved in, for example, the connective tissue remodeling that occurs in conjunction with inflammation. Although their effects may be beneficial to the host, for instance in the event of helminthic infestation, they may also cause tissue damage, for example in allergy and asthma. Recent years have witnessed significant advances in our knowledge of these fascinating but still enigmatic cells. The eosinophil granulocyte was first described in 1879 by Paul Ehrlich, who discovered a blood cell that had high affinity for acid dyes and, in particular, eosin (1) (Figure 1). Eosin, which gives the cells their characteristic red-orange color, is named after Eos, the goddess of dawn in Greek mythology. Paul Ehrlich also put forward the hypothesis that eosinophils develop in the bone marrow (2) and exert their functions in the peripheral tissues. All vertebrates seem to have eosinophils in their blood, but these cells have also been described in more primitive organisms such as sharks, turtles and snakes (3). However. there are differences in morphology, and a comparison of eosinophils from different species also reveals considerable differences in the protein content of their characteristic cytoplasmic granules. For example, in contrast to many vertebrates, eosinophils from the cat, rhino, hyena and okapi lack peroxidase (3).

Identifiers

PMID30720250
PMCPMC6357243
OpenAlexW2954027219

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.